肾移植后C3肾小球病与免疫复合物介导膜增生性肾小球肾炎复发:挑战与机遇
本综述聚焦肾移植后复发性C3肾小球病(C3G)和原发性免疫复合物介导膜增生性肾小球肾炎(IC-MPGN),阐述其发病机制涉及遗传易感性、获得性补体失调和移植相关触发因素,但尚无明确验证的复发预测因子。复发率常超过60%并与移植肾衰竭进展相关,早期发现可通过方案活检实现,而补体靶向治疗显示前景但时机和安全性未定。
要点
- 移植后C3G和IC-MPGN复发率常超过60%,与移植肾衰竭进展相关。
- 方案活检有助于早期发现复发,但早期组织学识别具有挑战性。
- 补体靶向治疗(如eculizumab、iptacopan、pegcetacoplan)显示前景,但最佳时机和长期安全性未明确。
核心结论
- 复发性C3G和IC-MPGN是移植肾失功的重要原因,补体靶向治疗带来希望但需进一步明确应用策略。
研究设计与样本
- 本文为综述,检索范围未在摘要中明确报告。
主要发现
- 复发率常超过60%,与移植肾衰竭进展相关。
- 发病机制涉及遗传易感性、获得性补体失调和移植相关触发因素,但无明确验证的复发预测因子。
- 早期发现可通过方案活检实现,但早期复发的组织学识别具有挑战性。
- 传统治疗包括强化免疫抑制、利妥昔单抗和血浆置换疗效有限且不一致。
- 补体靶向治疗显示前景,eculizumab研究最广泛,iptacopan和pegcetacoplan在原生和复发疾病中显示令人鼓舞的疗效。
关键数值与推荐
- 复发率常超过60%。
- eculizumab是研究最广泛的补体靶向药物。
- iptacopan和pegcetacoplan在原生和复发疾病中显示令人鼓舞的疗效。
临床怎么用
- 移植前综合评估包括遗传和分子补体检测及单克隆丙种球蛋白病筛查,可能优化风险分层。
- 方案活检有助于早期发现复发,为及时干预提供机会。
- 补体靶向治疗可用于复发性C3G和IC-MPGN,但最佳时机、预防性使用和长期安全性在移植受者中仍不确定。
局限性
- 无明确验证的复发预测因子。
- 早期复发的组织学识别具有挑战性。
- 补体靶向治疗在移植受者中的最佳时机、预防性使用和长期安全性不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurrent C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) remain major causes of kidney allograft dysfunction and loss. Their pathogenesis involves genetic susceptibility, acquired complement dysregulation, and transplant-related triggers, yet no clear validated predictors of recurrence exist. Recurrence rates after kidney transplantation frequently exceed 60% and are associated with progression to graft failure. Early detection, often achievable through protocol biopsies, offers an opportunity for timely intervention, although histologic recognition of early recurrence can be challenging. Comprehensive pretransplant evaluation, including genetic and molecular complement testing and screening for monoclonal gammopathies, may refine risk stratification. Conventional treatments, including intensified immunosuppression, rituximab, and plasma exchange, have shown limited and inconsistent efficacy. Conversely, complement-targeted therapies have yielded promising outcomes. Although eculizumab remains the most extensively studied agent, emerging proximal complement inhibitors such as iptacopan and pegcetacoplan have shown encouraging efficacy in both native and recurrent disease. However, optimal timing, prophylactic use, and long-term safety in transplant recipients remain uncertain. In this review, we outline the clinical spectrum, key diagnostic and therapeutic challenges, and emerging treatment strategies for recurrent C3G and IC-MPGN, highlighting advances that may ultimately improve graft survival and patient outcomes.
引用
- Ruiz-Cabello JE, Trujillo H, Cavero T, et al. Recurrence of C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis After Kidney Transplantation: Challenges and Opportunities. Kidney Int Rep. 2025. PMID: 41502804. doi:10.1016/j.ekir.2025.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。